Searched for
GSK SHARE PRICE
Ahead of Market: 10 things that will decide stock market action on MondayMarkets rallied sharply as easing US–Iran tensions and softer crude prices boosted sentiment. Sensex and Nifty surged 2%, adding Rs 10 lakh...- Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...
- Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapseThe US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion...
- US stocks: US market rises as tech shares gain, Middle East tensions easeWall Street indexes opened higher on Tuesday, driven by a second consecutive day of gains for chipmakers. Easing Middle East tensions also ...
- Global Markets: European shares edge higher with banks in the lead; the Middle East in focusEuropean markets saw a rise on Tuesday. Banking stocks led the gains, with Italian lenders drawing attention. Tech stocks stabilized after ...
- Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premiumInvestors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date i...
- Global Markets | European markets dip as investors eye earnings, Iran conflict continues to weighEuropean shares dipped on Wednesday, as investors turned their focus to a packed day of corporate earnings, while a continuing U.S.-Iran im...
- GSK intends to sell its remaining stake in HaleonGSK, which initially retained a near 13% stake in Haleon, had over the course of a year lowered its stake to 4.2%. Last year, GSK had said ...
- GSK to buy Canada's Bellus Health for $2 blnThe acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with ref...
- Glaxosmithkline Pharma Q1 Results: Net profit rises 8% to Rs 116 crore"Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth wit...
- GSK Pharma sheds 2% as Q3 profit drops, expenses riseTotal income in October-December 2021 stood at Rs 826.24 crore as compared with Rs 805.89 crore in the year-ago period, PTI reported.
- GSK Pharma Q3 results: Net profit jumps over two-folds to Rs 204 crThe company had reported a net profit of Rs 76.47 crore in the same period of the previous fiscal.
- GSK to boost spending power of pharma business post break-upGlaxoSmithKline will lay out plans to boost the spending power of its research-focused pharmaceuticals business at an investor day. GSK's s...
- GSK, Horlicks to sell HUL shares worth Rs 26,000 crore todayJP Morgan, Morgan Stanley and HSBC are the book runners to the trade.
- Unilever used HUL buyback gains to secure GSK health dealUnilever bought back HUL shares at Rs 600 apiece 5 years ago which has appreciated to Rs 1,700 now. Unilever diluted 5.3% HUL stake in GSK ...
- GSK Consumer jumps over 1% on merger with HULThe scrip was 1.57 per cent up at Rs 7,383.85 at around 02.27 pm.
- Minority investors to gain from GSK’s strategic reviewGSK CH’s sales are down from Rs 4,683 crore in FY14 to Rs 3,986 crore in FY17.
- $1 billion bet: GSK Pharma a short-term sell, long-term buy, say expertsThe stock is at rich valuations despite low sales and profit growth. The open offer by its parent firm is attractively priced, say experts.
- GSK Pharma rallies 20% as parent initiates open offerThe parent of GlaxoSmithKline Pharmaceuticals Ltd plans to increase its stake from 50.7 per cent to up to 75 per cent at an offer price of ...
- GSK to raise stake in GlaxoSmithKline Consumer Healthcare via open offerGlaxoSmithKline plans to raise its stake in its Indian consumer products arm to 75 per cent from 43.16 per cent through an open offer.
Load More
